麻豆传媒

Meeting Coverage >

ADA

Two T1D Patients Achieve Insulin Independence After Stem Cell Transplants

These were patients with "really debilitating diabetes," says investigator

High-Dose Semaglutide Pill Just as Effective as Wegovy for Weight Loss

Another study showed two high doses were better at reducing HbA1c vs a 14-mg dose

Novel Triple Agonist Nabs Biggest Weight Loss Yet in Obesity Trial

Plus, two other studies on retatrutide show benefit in type 2 diabetes, fatty liver disease

Bempedoic Acid Gets 'Huge' Win for Primary Prevention in the Statin-Intolerant

More positive results in CLEAR Outcomes sub-analysis

Once-Weekly Insulin Icodec Bests Daily Insulin Options for Type 2 Diabetes

Superior to once-a-day insulin glargine U100 and degludec

Near 15% Weight Loss With Novel Oral GLP-1 RA in Phase II Obesity Trial

Daily orforglipron also lowered HbA1c in type 2 diabetes

ADA 2022: Racial Residential Segregation, DKA During COVID, and More

Noteworthy research presented at the American Diabetes Association annual meeting

Don't Ignore Depression in Youth With Type 1 Diabetes

Depressive symptoms and history of suicide attempts linked with higher HbA1c

DIY Insulin Delivery System Safe, Effective for All Ages

Users spent more time in target glucose range than those on sensor augmented pump therapy

Concerning Trends in Vision Impairment for Adults With Diabetes?

Steady decreases in the prevalence of patients with eye problems may be over

T1D Patient Achieves Full Insulin Independence After Stem Cell Transplant

But clinical trial currently under FDA hold as dosing is discussed

Tirzepatide Reduced Albuminuria in T2D Patients With Heart Risk

Subanalysis of SURPASS-4 trial compared the GLP-1/GIP agonist against insulin glargine

Is Diabetes a Risk Factor for Long COVID? Possibly.

Mixed results in seven-study scoping review

Dulaglutide Improves HbA1c for Youth With Type 2 Diabetes

Safety profile consistent with that reported in adults

Tirzepatide Serves Up Major Weight-Loss Win in Patients With Obesity

SURMOUNT-1 trial tested GIP/GLP-1 receptor agonist in people without diabetes

Bariatric Surgery Cuts Cancer Incidence, Death Risk

Study looked at people with obesity who underwent two most popular procedures

CDC Study: Income-Related Inequalities Widening in Diabetes

Disparities differed by sex and age group

ADA 2021 Roundup: SoliMix Trial; Byetta for Teens; Driving in Hypoglycemia

Noteworthy research from the American Diabetes Association virtual meeting

Genetics, Socioeconomic Factors Each Tied to Diabetes and Obesity

People with highest risk genetics more than 15 times more likely to have T2D

Liraglutide and Insulin Come Out on Top for Glycemic Control in GRADE study

Head-to-head comparison could help individualize treatment

COVID-19 Pandemic Upped Anxiety in Adults, Kids With Diabetes

Providers should be screening patients on how COVID is affecting them, says researcher

Investigational GLP-1 RA Cuts Heart, Renal Risk in Vulnerable Diabetes Patients

Exendin-4-based drug succeeded in cardiovascular outcomes trial

180-Day Continuous Glucose Monitor Shows Promise in Adults With Diabetes

Implantable Eversense system demonstrates accuracy in prospective study

Hospitalization Rates for New-Onset Type 2 Diabetes in Kids Took Off During Pandemic

"COVID-19 disrupted our lives in more ways than we realize"

Combo GIP/GLP-1 Drug Superior for HbA1c Reduction in T2D

40-week trial compared tirzepatide head-to-head with injectable semaglutide

Ertugliflozin Tx: Safe for the Heart in Patients With T2D

Phase III VERTIS-CV trial meets primary endpoint of MACE non-inferiority

No Added CV Risk for Oral Semaglutide in T2D

Safety study buffs resume for oral GLP-1 receptor agonist

Urine Marker Predicts Kidney Benefit With Trulicity

Secondary AWARD-7 analysis finds subgroup getting the most renal protection

Dapagliflozin Boosts Renal Function in T2D

Secondary outcomes build on previously reported cardiovascular benefit from SGLT2 inhibitors

Another GLP-1 Agent Cuts Heart Risk in T2D

Dulaglutide added to the growing list of diabetes treatments to show added benefit

Novel Anti-CD3 Antibody Delays Progression to T1D

Single course of teplizumab slowed march to clinical type 1 diabetes in high-risk people

Expert Panel Defines CGM Time-in-Range Targets

Seventy percent of readings should stay between 70-180 mg/dL, according to recommendations

Vitamin D Flops for Diabetes Prevention

Highly anticipated trial finds no significant difference compared to placebo after nearly three years follow-up

SGLT-2 Inhibitors Tied to Lower All-Cause Mortality Risk

Head-to-head comparison with DPP-4 inhibitors also showed heart protection

'Artificial Pancreas' System Boosts In-Hospital T2D Control

Less time out of range, no increase in insulin or lows with fully-automated system

Early T2D Treatment in Youth Disappoints

Metformin, insulin didn't stop deterioration of beta-cells in adolescents with impaired glucose

TB Vaccine for T1D Study Stirs Controversy

Long-term data suggest BCG vaccine may alter immune attack

Intensive Treatment Doesn't Cost More

Therapy aimed at treating all organ targets extends life

Farxiga Lowers HbA1c in Type 1 Diabetes

Weight loss also accompanied better glycemic control

Eversense CGM Comes Out on Top for Accuracy in T1D

Dexcom G5 performed best in hypoglycemia

1